MYC and lymphoma: Surprisingly, we found no significant difference in the rate of onset of lymphoma in Eμ-Myc/p53+/−/Runx1fl/fl mice with active Cre recombinase (Figure 1A, 1B), initially suggesting that Runx1 loss had no effect on tumor onset.